| Predicted Trait | |
| Reported Trait | Nonmucinous Epithelial Ovarian Cancer |
| Mapped Trait(s) | ovarian carcinoma (EFO_0001075) |
| Score Construction | |
| PGS Name | PRS22_OCstepwise |
| Development Method | |
| Name | Stepwise method |
| Parameters | NR |
| Variants | |
| Original Genome Build | GRCh37 |
| Number of Variants | 22 |
| Effect Weight Type | beta |
| PGS Source | |
| PGS Catalog Publication (PGP) ID | PGP000474 |
| Citation (link to publication) | Hurwitz LM et al. JAMA Netw Open (2023) |
| Ancestry Distribution | |
| Source of Variant Associations (GWAS) | European: 100% 63,702 individuals (100%) |
| PGS Evaluation | |
| Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
|---|---|---|---|
Europe PMC: 35027648 |
[
|
European | OCAC |
|
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|
| PPM018518 | PSS011005| Multi-ancestry (including European)| 11,135 individuals |
PGP000474 | Hurwitz LM et al. JAMA Netw Open (2023) |
Reported Trait: Nonmucinous Epithelial Ovarian Cancer x aspirin use interaction | — | — | Odds ratio (OR, <median): 0.85 [0.7, 1.02] Odds ratio (OR, >=median): 0.86 [0.74, 1.01] |
— | — |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS011005 | — | — | [
|
— | African American or Afro-Caribbean (Black) |
— | OCAC | — |
| PSS011005 | — | — | [
|
— | European | — | OCAC | — |
| PSS011005 | — | — | [
|
— | Not reported | — | OCAC | — |